A new approach to drug design can deliver medicine directly to the gut in mice at significantly lower doses than current inflammatory bowel disease treatments. The proof-of-concept study introduced a ...

In patients with IBD on maintenance IFX, use of 5-ASA and immunomodulators does not significantly reduce flares, infections, or adverse reactions.